Korea Cancer Center Hospital

Seoul 139-706

0 studies enrolling now · 18 studies all time

What they study most

Advanced Ovarian Cancer, BRCA Mutation, Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Adenosquamous Cell Carcinoma, Cervical Cancer, Cervical Small Cell Carcinoma, Cervical Squamous Cell Carcinoma, Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Choriocarcinoma, Clear Cell Adenocarcinoma, Complete Response

Studies at this site

• Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer — Running, not enrolling
• Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer — Running, not enrolling
• INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC — Running, not enrolling
• Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer — Running, not enrolling
• Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy — Completed
• Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer — Running, not enrolling
• Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy. — Running, not enrolling
• A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy — Running, not enrolling
• Radiation Therapy With or Without Chemotherapy in Patients With Stage I-IIA Cervical Cancer Who Previously Underwent Surgery — Completed
• Studying the Physical Function and Quality of Life Before and After Surgery in Patients With Stage I Cervical Cancer — Status unconfirmed
• Dactinomycin or Methotrexate in Treating Patients With Low-Risk Gestational Trophoblastic Neoplasia — Completed
• Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer — Status unconfirmed
• Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer — Status unconfirmed
• Sunitinib Malate in Treating Patients With Persistent or Recurrent Clear Cell Ovarian Cancer — Completed
• Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III-IV Clear Cell Ovarian Cancer — Completed
• Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer — Completed
• Fludeoxyglucose (FDG) F 18 PET Scan, CT Scan, and Ferumoxtran-10 MRI Scan Before Chemotherapy and Radiation Therapy in Finding Lymph Node Metastasis in Patients With Locally Advanced Cervical Cancer or High-Risk Endometrial Cancer — Completed
• Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer — Status unconfirmed